ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag methyltransferases digital pcr personalized medicine

2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Top 10 Innovations 2014
The Scientist | Dec 1, 2014 | 10+ min read
The list of the year’s best new products contains both perennial winners and innovative newcomers.
Fighting Fraud With DNA
Bennett Daviss | Jun 20, 2004 | 8 min read
Next time you buy a designer shirt, be sure to check the label. What you don't see may surprise you. Hidden within the ink or fibers of that shirt could lie an authentication device made not of plastic or metal, but of DNA."DNA has become the gold standard, the highest barrier to product counterfeiting, diversion, and piracy," says Julia Hunter, executive vice president of Applied DNA Sciences in Los Angeles. In this case, though, the term gold is both literal and figurative. The International C
Prospecting for Gold in Genome Gulch
Amy Adams | Apr 14, 2002 | 9 min read
The human genome is much like the American West of the 1850s: Everyone wants a piece of the pie. Similar to gold prospectors of 150 years ago, biotech and pharmaceutical companies, and even universities, are frantically searching for the nuggets of gold that will help them find the mother lode—a gene whose function is sufficiently marketable to make all of the preliminary research worthwhile. Companies that do strike gold get to introduce new classes of drugs to the market. Others hope to
Beyond Sanger: Toward the $1,000 Genome
Aileen Constans | Jun 29, 2003 | 10 min read
Courtesy of Solexa Total Genotyping Without a doubt, the quarter-century-old Sanger sequencing method performed like a champ during the Human Genome Project. But with the capacity to read only a few hundred bases per reaction, it is far too slow and expensive for routine use in clinical settings. Reaping the rewards of the genomics era will clearly require faster and cheaper alternatives. Some companies estimate that within the next five years, technical advances could drop the cost of seque

Run a Search

ADVERTISEMENT